Literature DB >> 35100424

Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities.

Christopher A Alvarez-Breckenridge1, Daniel P Cahill2, Priscilla K Brastianos3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35100424      PMCID: PMC9071327          DOI: 10.1093/neuonc/noac017

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  10 in total

Review 1.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

2.  Trabectedin has promising antineoplastic activity in high-grade meningioma.

Authors:  Matthias Preusser; Sabine Spiegl-Kreinecker; Daniela Lötsch; Adelheid Wöhrer; Maria Schmook; Karin Dieckmann; Walter Saringer; Christine Marosi; Walter Berger
Journal:  Cancer       Date:  2012-03-05       Impact factor: 6.860

3.  Role of macrophage targeting in the antitumor activity of trabectedin.

Authors:  Giovanni Germano; Roberta Frapolli; Cristina Belgiovine; Achille Anselmo; Samantha Pesce; Manuela Liguori; Eugenio Erba; Sarah Uboldi; Massimo Zucchetti; Fabio Pasqualini; Manuela Nebuloni; Nico van Rooijen; Roberta Mortarini; Luca Beltrame; Sergio Marchini; Ilaria Fuso Nerini; Roberta Sanfilippo; Paolo G Casali; Silvana Pilotti; Carlos M Galmarini; Andrea Anichini; Alberto Mantovani; Maurizio D'Incalci; Paola Allavena
Journal:  Cancer Cell       Date:  2013-02-11       Impact factor: 31.743

4.  Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

Authors:  Matthias Preusser; Antonio Silvani; Emilie Le Rhun; Riccardo Soffietti; Giuseppe Lombardi; Juan Manuel Sepulveda; Petter Brandal; Lucy Brazil; Alice Bonneville-Levard; Veronique Lorgis; Elodie Vauleon; Jacoline Bromberg; Sara Erridge; Alison Cameron; Florence Lefranc; Paul M Clement; Sarah Dumont; Marc Sanson; Charlotte Bronnimann; Carmen Balaná; Niklas Thon; Joanne Lewis; Maximilian J Mair; Philipp Sievers; Julia Furtner; Josef Pichler; Jordi Bruna; Francois Ducray; Jaap C Reijneveld; Christian Mawrin; Martin Bendszus; Christine Marosi; Vassilis Golfinopoulos; Corneel Coens; Thierry Gorlia; Michael Weller; Felix Sahm; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

5.  Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Authors:  Elena Mazza; Alba Brandes; Silvia Zanon; Marika Eoli; Giuseppe Lombardi; Marina Faedi; Enrico Franceschi; Michele Reni
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-11       Impact factor: 3.333

6.  Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.

Authors:  Victoria E Clark; E Zeynep Erson-Omay; Akdes Serin; Jun Yin; Justin Cotney; Koray Ozduman; Timuçin Avşar; Jie Li; Phillip B Murray; Octavian Henegariu; Saliha Yilmaz; Jennifer Moliterno Günel; Geneive Carrión-Grant; Baran Yilmaz; Conor Grady; Bahattin Tanrikulu; Mehmet Bakircioğlu; Hande Kaymakçalan; Ahmet Okay Caglayan; Leman Sencar; Emre Ceyhun; A Fatih Atik; Yaşar Bayri; Hanwen Bai; Luis E Kolb; Ryan M Hebert; S Bulent Omay; Ketu Mishra-Gorur; Murim Choi; John D Overton; Eric C Holland; Shrikant Mane; Matthew W State; Kaya Bilgüvar; Joachim M Baehring; Philip H Gutin; Joseph M Piepmeier; Alexander Vortmeyer; Cameron W Brennan; M Necmettin Pamir; Türker Kiliç; Richard P Lifton; James P Noonan; Katsuhito Yasuno; Murat Günel
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Authors:  Yongli Ji; Cathryn Rankin; Steven Grunberg; Andy E Sherrod; Jamshid Ahmadi; Jeannette J Townsend; Lynn G Feun; Ruth K Fredericks; Christy A Russell; Fairooz F Kabbinavar; Keith J Stelzer; Anne Schott; Claire Verschraegen
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

8.  Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Authors:  G Huygh; Paul M J Clement; H Dumez; P Schöffski; H Wildiers; J Selleslach; J M Jimeno; I De Wever; R Sciot; L Duck; A T Van Oosterom
Journal:  Sarcoma       Date:  2006-12-31

9.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Authors:  Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.